Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Validity of Natural Language Processing for Ascertainment of EGFR and ALK Test Results in SEER Cases of Stage IV Non-Small-Cell Lung Cancer.

Goulart BHL, Silgard ET, Baik CS, Bansal A, Sun Q, Durbin EB, Hands I, Shah D, Arnold SM, Ramsey SD, Kavuluru R, Schwartz SM.

JCO Clin Cancer Inform. 2019 May;3:1-15. doi: 10.1200/CCI.18.00098.


Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.

Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE.

Lung Cancer. 2019 Feb;128:74-90. doi: 10.1016/j.lungcan.2018.12.003. Epub 2018 Dec 6.


Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE.

Clin Cancer Res. 2019 Jan 1;25(1):64-72. doi: 10.1158/1078-0432.CCR-18-1590. Epub 2018 Sep 11.


Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.

Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL, Chow LQM.

Clin Cancer Res. 2017 Sep 1;23(17):4992-5002. doi: 10.1158/1078-0432.CCR-16-3066.


Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.

Baik CS, Myall NJ, Wakelee HA.

Oncologist. 2017 Jul;22(7):786-796. doi: 10.1634/theoncologist.2016-0458. Epub 2017 May 9. Review.


Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ.

Neuro Oncol. 2017 Jan;19(1):i1-i24. doi: 10.1093/neuonc/now197. Review.


Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.

Pellini Ferreira B, Redman M, Baker KK, Martins R, Eaton KD, Chow LQM, Baik CS, Goulart B, Lee SM, Santana-Davila R, Rodriguez CP.

Laryngoscope. 2017 Jul;127(7):1583-1588. doi: 10.1002/lary.26422. Epub 2016 Dec 1.


Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.

Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3.


Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.


Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.

Baik CS, Wu D, Smith C, Martins RG, Pritchard CC.

J Thorac Oncol. 2015 Oct;10(10):e97-9. doi: 10.1097/JTO.0000000000000586. No abstract available.


Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer.

Baik CS, Chamberlain MC, Chow LQ.

J Thorac Oncol. 2015 Sep;10(9):1268-1278. doi: 10.1097/JTO.0000000000000615. Review.


Nonsteroidal Anti-Inflammatory Drug and Aspirin Use in Relation to Lung Cancer Risk among Postmenopausal Women.

Baik CS, Brasky TM, Pettinger M, Luo J, Gong Z, Wactawski-Wende J, Prentice RL.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):790-7. doi: 10.1158/1055-9965.EPI-14-1322. Epub 2015 Feb 10.


Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative.

Brasky TM, Liu J, White E, Peters U, Potter JD, Walter RB, Baik CS, Lane DS, Manson JE, Vitolins MZ, Allison MA, Tang JY, Wactawski-Wende J.

Int J Cancer. 2014 Oct 15;135(8):1869-83. doi: 10.1002/ijc.28823. Epub 2014 Mar 20.


Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-institutional Experience.

Yan J, Liu Q, Moseley JN, Baik CS, Chow LQ, Goulart BH, Zlotnick D, Papanicolau-Sengos A, Gallaher I, Knopp JM, Zeng J, Patel S.

Am J Clin Oncol. 2016 Jun;39(3):223-7. doi: 10.1097/COC.0000000000000044.


The role of chemotherapy in the management of stage IIIA non-small cell lung cancer.

Baik CS, Vallières E, Martins RG.

Am Soc Clin Oncol Educ Book. 2013:320-5. doi: 10.1200/EdBook_AM.2013.33.320. Review.


EGFR mutations in squamous cell lung cancer in never-smokers.

Baik CS, Pritchard CC, Eaton KD, Chow LQ.

J Thorac Oncol. 2013 Jan;8(1):e6-7. doi: 10.1097/JTO.0b013e3182762d49. No abstract available.


Prediagnostic nonsteroidal anti-inflammatory drug use and lung cancer survival in the VITAL study.

Brasky TM, Baik CS, Slatore CG, Alvarado M, White E.

J Thorac Oncol. 2012 Oct;7(10):1503-12.


Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in the VITAL study.

Brasky TM, Baik CS, Slatore CG, Potter JD, White E.

Lung Cancer. 2012 Aug;77(2):260-4. doi: 10.1016/j.lungcan.2012.04.015. Epub 2012 May 17.


Estrogen signaling in lung cancer: an opportunity for novel therapy.

Baik CS, Eaton KD.

Cancers (Basel). 2012 Sep 25;4(4):969-88. doi: 10.3390/cancers4040969.


Differentiation of human labia minora dermis-derived fibroblasts into insulin-producing cells.

Kim B, Yoon BS, Moon JH, Kim J, Jun EK, Lee JH, Kim JS, Baik CS, Kim A, Whang KY, You S.

Exp Mol Med. 2012 Jan 31;44(1):26-35. doi: 10.3858/emm.2012.44.1.002.


Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer.

Hanash SM, Baik CS, Kallioniemi O.

Nat Rev Clin Oncol. 2011 Mar;8(3):142-50. doi: 10.1038/nrclinonc.2010.220. Review.


Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study.

Baik CS, Strauss GM, Speizer FE, Feskanich D.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2525-33. doi: 10.1158/1055-9965.EPI-10-0450. Epub 2010 Aug 25.


[Down-Turner syndrome (45,X/47,XY,+21): case report and review].

Ryu SW, Lee G, Baik CS, Shim SH, Kim JT, Lee JS, Lee KA.

Korean J Lab Med. 2010 Apr;30(2):195-200. doi: 10.3343/kjlm.2010.30.2.195. Review. Korean.


Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis.

Choi MR, Kim HY, Park JY, Lee TY, Baik CS, Chai YG, Jung KH, Park KS, Roh W, Kim KS, Kim SH.

Neurosci Lett. 2010 Mar 19;472(2):94-8. doi: 10.1016/j.neulet.2010.01.054. Epub 2010 Feb 1.


Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells.

Yoon BS, Moon JH, Jun EK, Kim J, Maeng I, Kim JS, Lee JH, Baik CS, Kim A, Cho KS, Lee JH, Lee HH, Whang KY, You S.

Stem Cells Dev. 2010 Jun;19(6):887-902. doi: 10.1089/scd.2009.0138.


Supplemental Content

Support Center